Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:CYCC's Cash to Debt is ranked higher than
93% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:CYCC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:CYCC' s Cash to Debt Range Over the Past 10 Years
Min: 1  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.70
NAS:CYCC's Equity to Asset is ranked higher than
52% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:CYCC: 0.70 )
Ranked among companies with meaningful Equity to Asset only.
NAS:CYCC' s Equity to Asset Range Over the Past 10 Years
Min: -3.51  Med: 0.76 Max: 0.88
Current: 0.7
-3.51
0.88
Interest Coverage No Debt
NAS:CYCC's Interest Coverage is ranked higher than
90% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:CYCC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:CYCC' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: -24.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -985.91
NAS:CYCC's Operating margin (%) is ranked lower than
76% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:CYCC: -985.91 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:CYCC' s Operating margin (%) Range Over the Past 10 Years
Min: -25222.48  Med: -4811.63 Max: -831.79
Current: -985.91
-25222.48
-831.79
Net-margin (%) -807.55
NAS:CYCC's Net-margin (%) is ranked lower than
75% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:CYCC: -807.55 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:CYCC' s Net-margin (%) Range Over the Past 10 Years
Min: -19110.14  Med: -4605.02 Max: -737.76
Current: -807.55
-19110.14
-737.76
ROE (%) -65.65
NAS:CYCC's ROE (%) is ranked lower than
69% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:CYCC: -65.65 )
Ranked among companies with meaningful ROE (%) only.
NAS:CYCC' s ROE (%) Range Over the Past 10 Years
Min: -156.88  Med: -98.34 Max: -42.99
Current: -65.65
-156.88
-42.99
ROA (%) -49.17
NAS:CYCC's ROA (%) is ranked lower than
68% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:CYCC: -49.17 )
Ranked among companies with meaningful ROA (%) only.
NAS:CYCC' s ROA (%) Range Over the Past 10 Years
Min: -86.17  Med: -58.95 Max: -34.56
Current: -49.17
-86.17
-34.56
ROC (Joel Greenblatt) (%) -7220.65
NAS:CYCC's ROC (Joel Greenblatt) (%) is ranked lower than
83% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:CYCC: -7220.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:CYCC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -10207.43  Med: -3822.33 Max: -1007.24
Current: -7220.65
-10207.43
-1007.24
Revenue Growth (3Y)(%) 92.80
NAS:CYCC's Revenue Growth (3Y)(%) is ranked higher than
93% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. NAS:CYCC: 92.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:CYCC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -23 Max: 92.8
Current: 92.8
0
92.8
EBITDA Growth (3Y)(%) -35.40
NAS:CYCC's EBITDA Growth (3Y)(%) is ranked lower than
85% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:CYCC: -35.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:CYCC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.2  Med: -31.7 Max: 13.8
Current: -35.4
-50.2
13.8
EPS Growth (3Y)(%) -36.40
NAS:CYCC's EPS Growth (3Y)(%) is ranked lower than
84% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. NAS:CYCC: -36.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:CYCC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.8  Med: -32.3 Max: 19.3
Current: -36.4
-50.8
19.3
» NAS:CYCC's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-12)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CYCC Guru Trades in Q3 2015

Jim Simons Sold Out
» More
Q4 2015

CYCC Guru Trades in Q4 2015

Jim Simons 145,294 sh (New)
» More
Q1 2016

CYCC Guru Trades in Q1 2016

Jim Simons 279,094 sh (+92.09%)
» More
Q2 2016

CYCC Guru Trades in Q2 2016

Jim Simons 44,613 sh (+91.82%)
» More
» Details

Insider Trades

Latest Guru Trades with CYCC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Cyclacel Pharmaceuticals Inc

SymbolPriceYieldDescription
CYCCP7.008.576% Convertible Exchangeable Preferred Stock

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCBB:RGBP, OTCPK:ETST, OTCPK:AYTUD, OTCPK:ARNI, NAS:STEM, NAS:BSTG, OTCPK:GBLX, AMEX:APHB, NAS:NEOT, OTCPK:ENDV, NAS:APOP, NAS:CSBR, NAS:CBLI, OTCPK:ENZN, OTCBB:DDRT, OTCPK:OPNT, NAS:MATN, OTCPK:BCTXF, NAS:CBIO, AMEX:IMUC » details
Traded in other countries:UXI3.Germany,
Cyclacel Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases.

Cyclacel Pharmaceuticals Inc was founded in August 13, 1996 and is incorporated in Delaware. The Company is a biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. The Company develops and commercializes small-molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, particularly those of high unmet medical need. Its clinical development priorities are focused on sapacitabine only, its second drug candidate, seliciclib, is a novel, orally-available, CDK clinical development priorities are focused on sapacitabine as an orphan drug for the treatment of both Acute Myeloid Leukemia, or AML, and Myelodysplastic Syndromes, or MDS. The Company is currently evaluating sapacitabine in a Phase 3 study being conducted under a Special Protocol Assessment, or SPA, with the FDA for the front-line treatment of AML in the elderly. The Company is also exploring sapacitabine in Phase 2 studies for MDS, non-small cell lung cancer, or NSCLC, and chronic lymphocytic leukemia, or CLL and in a Phase 1 study in solid tumors in combination with seliciclib, another of its drug candidates. Sapacitabine has been evaluated in approximately 1,000 patients to date. In addition, in polo-like kinase, or PLK inhibitor program, the Company has discovered CYC140 and other small molecule inhibitors of PLK1, a kinase active during cell division, targeting the mitotic phase of the cell cycle. The Company retains all marketing rights for these compounds internationally.

Ratios

vs
industry
vs
history
P/B 1.30
CYCC's P/B is ranked higher than
89% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. CYCC: 1.30 )
Ranked among companies with meaningful P/B only.
CYCC' s P/B Range Over the Past 10 Years
Min: 0.22  Med: 1.99 Max: 13.13
Current: 1.3
0.22
13.13
P/S 10.82
CYCC's P/S is ranked higher than
53% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. CYCC: 10.82 )
Ranked among companies with meaningful P/S only.
CYCC' s P/S Range Over the Past 10 Years
Min: 5.02  Med: 68.21 Max: 9520
Current: 10.82
5.02
9520
Current Ratio 3.37
CYCC's Current Ratio is ranked lower than
59% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. CYCC: 3.37 )
Ranked among companies with meaningful Current Ratio only.
CYCC' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 3.98 Max: 12.96
Current: 3.37
0.96
12.96
Quick Ratio 3.37
CYCC's Quick Ratio is ranked lower than
57% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. CYCC: 3.37 )
Ranked among companies with meaningful Quick Ratio only.
CYCC' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 3.98 Max: 12.96
Current: 3.37
0.96
12.96
Days Sales Outstanding 366.95
CYCC's Days Sales Outstanding is ranked lower than
95% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. CYCC: 366.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYCC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 366.95  Med: 777.81 Max: 6980.27
Current: 366.95
366.95
6980.27

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -60.40
CYCC's 3-Year Average Share Buyback Ratio is ranked lower than
88% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CYCC: -60.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYCC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -144.5  Med: -43 Max: 0
Current: -60.4
-144.5
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.67
CYCC's Price/Net Cash is ranked higher than
92% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. CYCC: 1.67 )
Ranked among companies with meaningful Price/Net Cash only.
CYCC' s Price/Net Cash Range Over the Past 10 Years
Min: 0.55  Med: 2.44 Max: 9.34
Current: 1.67
0.55
9.34
Price/Net Current Asset Value 1.30
CYCC's Price/Net Current Asset Value is ranked higher than
94% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. CYCC: 1.30 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYCC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.45  Med: 2.26 Max: 6.19
Current: 1.3
0.45
6.19
Price/Tangible Book 1.30
CYCC's Price/Tangible Book is ranked higher than
92% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. CYCC: 1.30 )
Ranked among companies with meaningful Price/Tangible Book only.
CYCC' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.41  Med: 2.17 Max: 5.9
Current: 1.3
0.41
5.9
Price/Median PS Value 0.16
CYCC's Price/Median PS Value is ranked higher than
95% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. CYCC: 0.16 )
Ranked among companies with meaningful Price/Median PS Value only.
CYCC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 1.03 Max: 117.76
Current: 0.16
0.12
117.76
Earnings Yield (Greenblatt) (%) -855.61
CYCC's Earnings Yield (Greenblatt) (%) is ranked lower than
100% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. CYCC: -855.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYCC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -909.1  Med: 419.8 Max: 26714.3
Current: -855.61
-909.1
26714.3

More Statistics

Revenue (TTM) (Mil) $1.50
EPS (TTM) $ -4.25
Beta4.76
Short Percentage of Float4.66%
52-Week Range $3.60 - 12.60
Shares Outstanding (Mil)3.12

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1 2 11 54
EPS ($) -2.93 -5.48 -9.21 -1.26
EPS w/o NRI ($) -2.93 -5.48 -9.21 -1.26
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:CYCC

Headlines

Articles On GuruFocus.com
Wilbur Ross Buys Two New Stakes in First Quarter Jun 15 2015 
Insider Cluster Buying Reported in Several Companies May 30 2013 
Cyclacel Pharmaceuticals Inc. Reports Operating Results (10-K/A) May 17 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 

More From Other Websites
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Sep 12 2016
Cyclacel's CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data... Sep 06 2016
Cyclacel’s CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical... Sep 06 2016
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 30 2016
Movers and Shakers In Biotech: Cyclacel Pharmaceuticals Inc (CYCC) and Corium International Inc... Aug 23 2016
Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism Aug 22 2016
Here's Why Cyclacel Pharmaceuticals (CYCC) Stock Is Surging Today Aug 22 2016
ETF’s with exposure to Cyclacel Pharmaceuticals, Inc. : August 19, 2016 Aug 19 2016
CYCLACEL PHARMACEUTICALS, INC. Financials Aug 18 2016
Cyclacel Pharmaceuticals, Inc. :CYCC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18,... Aug 18 2016
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2016
Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results Aug 10 2016
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 10 2016
Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results Aug 10 2016
Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results Aug 03 2016
Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results Aug 03 2016
Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data... Aug 02 2016
Cyclacel’s CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data... Aug 02 2016
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jul 06 2016
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)